Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;4(5):281-96.
doi: 10.1177/1756285611413825.

The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

Volker Limmroth  1 , Norman Putzki, Norman J Kachuck
Affiliations

The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

Volker Limmroth et al. Ther Adv Neurol Disord. 2011 Sep.

Abstract

Interferon beta preparations are the most widely used initial therapies prescribed for patients with relapsing-remitting multiple sclerosis. Phase III studies have demonstrated comparable efficacy on clinical measures of disease activity, variable benefits on radiological measures, and good overall tolerability. Subsequent clinical studies have attempted to compare directly the three available interferon beta preparations, reporting both safety and efficacy data. We review the literature on studies evaluating interferon beta therapy for patients with relapsing-remitting multiple sclerosis, discuss reasons for discrepant findings, and assess the utility of interferon beta-based combination regimens as the focus of future studies in the increasingly complex multiple sclerosis therapy landscape.

Keywords: efficacy; interferon beta; multiple sclerosis; safety.

PubMed Disclaimer

References

    1. Bayer Healthcare Pharmaceuticals (2008) Betaseron (interferon beta-1b) prescribing information. Montville, NJ: Bayer Healthcare Pharmaceuticals, Inc
    1. Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P.B., Capobianco M., et al. (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73: 148–153 - PMC - PubMed
    1. Biogen Idec (2008) Avonex (intramuscular interferon beta-1a) prescribing information. Cambridge, MA: Biogen Idec, Inc
    1. Birnbaum G., Cree B., Altafullah I., Zinser M., Reder A.T. (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology DOI: 10.1212/01.wnl.0000319698.40024.1c - PubMed
    1. Boskovic R., Wide R., Wolpin J., Bauer D.J., Koren G. (2005) The reproductive effects of beta interferon therapy in pregnancy. A longitudinal cohort. Neurology 65: 807–811 - PubMed

LinkOut - more resources